Latest news with #OneSourceSpecialtyPharma
Reuters
an hour ago
- Business
- Reuters
India's OneSource eyes weight-loss drug boost to order book
June 12 (Reuters) - Indian contract drug manufacturer OneSource Specialty Pharma ( opens new tab expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said on Monday. Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk ( opens new tab and U.S.-based Eli Lilly (LLY.N), opens new tab. The active chemical compound in Novo's injectable Wegovy drug, semaglutide, will go off patent in 2026 in a few markets, including India. OneSource, which added 15 orders related to obesity and diabetes drugs in fiscal year 2025, said there are more in the pipeline. The global obesity market is estimated to be valued at $150 billion by the early 2030s. The company develops and manufactures complex biological drugs, vials, injectables, and soft gelatin capsules for larger pharmaceutical firms. "Our growth over the next few years will be driven by commercial launches of GLP-1s (weight-loss and diabetes drugs) by our global customers in all the key markets opening post patent expiry in 2026," CEO Neeraj Sharma told Reuters in an interview. Backed by increasing demand from weight-loss drug manufacturers, OneSource's order book across all service verticals should expand in line with 30% compound annual growth rate through fiscal year 2028, according to the CEO. OneSource, which competes with larger players such as Piramal Pharma ( opens new tab and Divi's ( opens new tab in contract research, development and manufacturing, is investing about $100 million to expand its drug device facilities, the CEO said. The company, which was demerged from Strides Pharma Science ( opens new tab and listed in January, is also looking at setting up a global footprint in manufacturing, both in Europe and the U.S.
Yahoo
an hour ago
- Business
- Yahoo
India's OneSource eyes weight-loss drug boost to order book
By Rishika Sadam (Reuters) -Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said on Monday. Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk and U.S.-based Eli Lilly. The active chemical compound in Novo's injectable Wegovy drug, semaglutide, will go off patent in 2026 in a few markets, including India. OneSource, which added 15 orders related to obesity and diabetes drugs in fiscal year 2025, said there are more in the pipeline. The global obesity market is estimated to be valued at $150 billion by the early 2030s. The company develops and manufactures complex biological drugs, vials, injectables, and soft gelatin capsules for larger pharmaceutical firms. "Our growth over the next few years will be driven by commercial launches of GLP-1s (weight-loss and diabetes drugs) by our global customers in all the key markets opening post patent expiry in 2026," CEO Neeraj Sharma told Reuters in an interview. Backed by increasing demand from weight-loss drug manufacturers, OneSource's order book across all service verticals should expand in line with 30% compound annual growth rate through fiscal year 2028, according to the CEO. OneSource, which competes with larger players such as Piramal Pharma and Divi's in contract research, development and manufacturing, is investing about $100 million to expand its drug device facilities, the CEO said. The company, which was demerged from Strides Pharma Science and listed in January, is also looking at setting up a global footprint in manufacturing, both in Europe and the U.S. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Standard
a day ago
- Business
- Business Standard
Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane
Onesource Specialty Pharma advanced 1.55% to Rs 2057 after the company announced a partnership with Sweden-based Xbrane Biopharma AB for manufacturing biosimilars for global markets. Xbrane Biopharma AB is a biotechnology company. It develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSources integrated drug substance and drug product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbranes global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbranes latest funding round, reinforcing the long-term alignment between the two companies. Neeraj Sharma, managing director & CEO of OneSource Specialty Pharma, said: The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbranes proven success in biosimilar development, combined with OneSources fully integrated biologics platform, creates a strong platform for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the worlds leading biotech companies. OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,200 professionals. On a consolidated basis, OneSource Specialty Pharma reported net profit of Rs 98.50 crore in Q4 March 2025 as against net loss of Rs 40.17 crore in Q4 March 2024. Net sales surged 482.38% YoY to Rs 425.95 crore in Q4 March 2025.
Business Standard
a day ago
- Business
- Business Standard
OneSource collaborates with Xbrane Biopharma AB
For commercial manufacturing of Xbrane's biosimilar portfolio OneSource Specialty Pharma and Xbrane Biopharma AB, a Sweden-headquartered biotechnology company, today announced a partnership focused on the commercial manufacturing of Xbrane's biosimilar portfolio. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference products. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSource's state-of the-art integrated Drug Substance and Drug Product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbrane's global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbrane's latest funding round, reinforcing the long-term alignment between the two companies.
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Mukul Agrawal portfolio stock hits record high; zooms 75% from March low
Share price of OneSource Specialty Pharma today: Shares of OneSource Specialty Pharma hit a new high of ₹2,031.45, as they rallied 5 per cent on the BSE in Tuesday's intra-day trade in otherwise a subdued market. At 01:49 PM, the BSE Sensex was up 0.02 per cent at 82,455. In the past month, the stock price of the pharmaceutical company has surged 28 per cent. It has bounced back 75 per cent from its March low price of ₹1,163.05 on the BSE. OneSource's Bangalore unit received VAI classification from USFDA OneSource Specialty Pharma today announced that its flagship facility in Bangalore received a "Voluntary Action Indicated" (VAI) classification from the US Food and Drug Administration (USFDA), confirming its continued compliance. Following an inspection of the company's flagship facility from March 20 to March 28, 2025, the USFDA issued a Form 483 with four observations. Based on the company's comprehensive response and commitments, the agency has classified the inspection outcome as VAI, officially closing the inspection, the company said in its exchange filing. Track LIVE Stock Market Updates Today Mukul Mahavir Agrawal holds over 1% stake in OneSource Ace Investor Mukul Mahavir Agrawal held 1.5 million equity shares representing a 1.31 per cent stake in OneSource Specialty Pharma at the end of the March 2025 quarter, the shareholding pattern data shows. As per the latest corporate shareholdings filed, Mukul Agrawal publicly holds stakes in Indo Count Industries, Deepak Fertilisers & Petrochemicals Corporation, Neuland Laboratories, Radico Khaitan, Nuvama Wealth Management, BSE and PTC Industries. India Ratings and Research (Ind-Ra) rating rationale The Positive Outlook reflects Ind-Ra's expectation that OneSource Specialty Pharma would continue to report healthy revenue/Ebitda in its softgel capsules (SGC)/injectable business (financials available only from Q3FY25 onwards) and the improved visibility on the commercialisation of its Glucagon-like peptide 1 (GLP-1) contracts. The drug device combination (DDC) segment is likely to register moderate growth in FY26, supported by a strong pipeline of master service agreement (MSA) contracts and the initiation of commercial supply agreement (CSA) revenues. Despite OneSource Specialty Pharma's capex plans for capacity enhancement, Ind-Ra expects the credit metrics to remain healthy in the near-to-medium term, aided by long-term contracts for the supply of GLP-1 products to its global clients. Ind-Ra said it will monitor OneSource Specialty Pharma's evolving revenue profile, product concentration risk and price volatility, which could have a bearing on its business profile in the medium-to-long term. Ind-Ra will also monitor the outcome of the arbitration in lieu of contingent liabilities of ₹1,000 crore on the books and its impact on the credit metrics, if any. About OneSource Specialty Pharma OneSource Specialty Pharma is a pure-play speciality pharmaceutical Contract Development and Manufacturing Organization (CDMO). The company focuses on the development and manufacturing of complex pharmaceutical products, including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatin capsules). Until FYE24, OneSource Specialty Pharma had capabilities in biologics and drug-device combination (DDC) products. In FY25, Strides Pharma Science's softgels business and Steriscience Pharma Pvt Ltd's injectables business was merged with OneSource Specialty Pharma, thereby augmenting OneSource Specialty Pharma's scale of operations.
